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RESEARCH ARTICLE Open Access
Black patients referred to a lung cancer
screening program experience lower rates
of screening and longer time to follow-up
Michael Lake1†, Christine S. Shusted2†, Hee-Soon Juon3, Russell K. McIntire4, Charnita Zeigler-Johnson3,
Nathaniel R. Evans5, Gregory C. Kane2 and Julie A. Barta1*
Abstract
Background: Racial disparities are well-documented in preventive cancer care, but they have not been fully
explored in the context of lung cancer screening. We sought to explore racial differences in lung cancer screening
outcomes within a lung cancer screening program (LCSP) at our urban academic medical center including
differences in baseline low-dose computed tomography (LDCT) results, time to follow-up, adherence, as well as
return to annual screening after additional imaging, loss to follow-up, and cancer diagnoses in patients with
positive baseline scans.
Methods: A historical cohort study of patients referred to our LCSP was conducted to extract demographic and
clinical characteristics, smoking history, and lung cancer screening outcomes.
Results: After referral to the LCSP, blacks had significantly lower odds of receiving LDCT compared to whites, even
while controlling for individual lung cancer risk factors and neighborhood-level factors. Blacks also demonstrated a
trend toward delayed follow-up, decreased adherence, and loss to follow-up across all Lung-RADS categories.
Conclusions: Overall, lung cancer screening annual adherence rates were low, regardless of race, highlighting the
need for increased patient education and outreach. Furthermore, the disparities in race we identified encourage
further research with the purpose of creating culturally competent and inclusive LCSPs.
Keywords: Lung Cancer Screening, Racial disparities, Lung Cancer, Cancer Screening, Lung Cancer diagnosis,
Screening adherence
Background
Lung cancer is the leading cause of cancer-related
mortality in the United States [1]. Cigarette smoking
is estimated to be linked to 80–90% of lung cancer
deaths, making it one of the most preventable cancer
deaths [1, 2]. After smoking cessation, one of the
most effective mechanisms for reducing lung cancer
mortality is through annual lung cancer screening
with low-dose computed tomography (LDCT). The
National Lung Screening Trial (NLST) showed that
annual screening of high-risk individuals with LDCT
offered a 20% relative decrease in lung cancer mortal-
ity and a 6.7% reduction in all-cause mortality when
compared with chest radiography [3]. Although the
NLST was published in 2011, and lung cancer screen-
ing was recommended for eligible persons by the
United States Preventive Services Task Force
(USPSTF) in 2013, lung cancer screening rates remain
low [3–5]. According to a recent study utilizing the
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American College of Radiology’s Lung Cancer Screen-
ing Registry data; in 2016, only 1.9% of the 7.6 mil-
lion eligible adults underwent LDCT [6]. Nationally,
screening rates vary widely based on geographic loca-
tion [6]. However, geography is not the only factor
that determines whether an individual will undergo
lung cancer screening.
The availability of new screening tests for early detec-
tion of cancer is associated with racial and socioeco-
nomic disparities in utilization, stage at diagnosis, and
mortality [7]. While some disparities have declined over
time, significant differences endure between black and
white patients undergoing cancer screening and treat-
ment [7–9]. Specifically, among patients with lung can-
cer, blacks are more likely to have advanced disease at
diagnosis, experience less definitive surgery, and have
lower rates of lung cancer survival than whites [10–14].
Although lung cancer incidence rates decreased faster in
blacks compared with whites from 2006 to 2015, lung
cancer diagnoses remain 15% higher in black men than
in white men [15]. Moreover, despite declining smoking
prevalence in black patients, black men continue to have
the highest lung cancer death rate of any racial or ethnic
group [15]. These disparities are the result of a complex
interplay of risk factors, including societal and environ-
mental factors, smoking characteristics, and tumor biol-
ogy [16]. Furthermore, there are conflicting data on the
influence of access to care, for example. While some
studies suggest that despite equalizing access to care,
blacks remain less likely to receive surgical resection,
others have shown that when access to care is controlled
for survival times are more equitable [11, 17–20]..
A secondary analysis of the NLST showed blacks
experience a greater reduction in mortality from
LDCT screening compared to whites [7]. Despite this
finding, blacks may not experience the full benefits of
lung cancer screening because blacks are less likely to
qualify for screening and are disproportionately less
likely to undergo screening [8, 21, 22]. Blacks are also
more likely to be unaware of screening, be under-
insured, and have lower socioeconomic status—all fac-
tors that contribute to decreased screening rates for
lung cancer [7, 11–14, 23].
Much of what is known about racial disparities in lung
cancer screening has been extrapolated from the NLST
or has been generalized from literature in other fields of
cancer screening [3]. However, only 4.5% of participants
in the NLST identified as black, despite the fact that six
of the 33 centers in the NLST developed minority ac-
crual programs to boost black enrollment [24]. These six
centers were located primarily in urban areas including
Atlanta and Baltimore, where the percentage of the black
population is 52.4 and 63%, respectively. Even with tar-
geted recruitment of minorities, enrollment of black
subjects into the NLST was only 9.5% collectively at
these institutions. Enrollment for other minority popula-
tions such as Asians and Hispanics were 0.9 and 1.7%
respectively. This reflects the larger issue of consistently
low minority participation in major clinical trials [24].
A number of studies are now focusing on the impact
of lung cancer screening among minority populations.
Most notably, Aldrich and colleagues recently evaluated
the diagnostic accuracy of USPSTF eligibility criteria in a
large, prospective screening cohort and found that a lar-
ger percentage of black smokers (compared with white
smokers) diagnosed with lung cancer would have been
ineligible for screening based upon age and pack-year
criteria alone [22]. Others have shown that black males
found to have stage I non-small cell lung cancer after
undergoing lung cancer screening have a lower probabil-
ity of receiving curative surgical resection compared to
white males [8, 25]. However, large gaps in knowledge
remain around racial disparities in lung cancer screen-
ing, particularly among LCSPs serving vulnerable popu-
lations in urban settings. We aimed to examine racial
differences in baseline CT, follow-up intervals, and ad-
herence among black and white patients enrolled in a
LCSP at an academic medical center in Philadelphia.
Methods
Study population
We carried out a historical cohort study of patients re-
ferred to our LCSP. Following approval by the Institu-
tional Review Board of Thomas Jefferson University
(17D.150), participants were identified using the clinical
databases of the Jane and Leonard Korman Respiratory
Institute Lung Cancer Screening Program. All referrals
to the Jefferson LCSP between May 2015 and July 2017
were included for analysis. We carried out retrospective
chart review for events that occurred through September
6th, 2019. Retrospective data were extracted from the
electronic medical record (EMR) regarding patient
demographics, interval time between follow-up scans,
and results of LDCT. For the purpose of this analysis, all
patients who were neither black nor white were ex-
cluded (Fig. 1). We did not exclude patients of Hispanic
origin. After examining racial differences between pa-
tients referred to the LCSP and those who underwent
screening, those who were never screened were excluded
from further analysis. We then explored racial differ-
ences in follow-up intervals and adherence in patients
who underwent at least one LDCT over the course of
the study period.
Lung Cancer Screening Program
Our LCSP is a centralized screening program within the
Korman Respiratory Institute and Division of Pulmonary
and Critical Care Medicine. Once a referral is generated
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by a primary care provider or specialist within the health
system, patients are reached via phone by a nurse navi-
gator or coordinator who describes the LCSP, deter-
mines eligibility, schedules an office visit, and obtains
insurance authorization for a screening LDCT scan. At
the office appointment, all patients receive in-person
shared decision-making by an advanced practice pro-
vider. Consistent with CMS and other professional
organization guidelines, shared decision making is an in-
formed discussion and counseling centered on the po-
tential benefits, limitations, and harms associated with
screening for lung cancer with LDCT [5, 26, 27]. If pa-
tients consent to proceeding with screening, in most
cases they have a same-day LDCT. Screening results are
communicated to patients via phone and to primary care
providers through the EMR. Patient navigation via a
dedicated nurse is essential to our program, as multiple
phone calls are made regarding appointment times,
results, and follow-up. After LDCT, patients with
significant findings are scheduled to be seen in our
multi-disciplinary Nodule Clinic to discuss further man-
agement. Patients who are due for a short-term or an-
nual follow-up are contacted via telephone by the LCSP
nurse navigator to schedule their visit. For patients who
are unreachable by phone, a reminder letter is mailed to
the patient and the patient’s primary care physician.
Measures
Outcomes
This analysis looked at lung cancer screening outcomes
across the care continuum. Referrals to the program
were logged, and patients’ compliance with screening
after referral was tracked as a dichotomous variable (0 =
no screening; 1 = screening). Among those screened, pa-
tients who were assigned Lung-RADS 1 or 2 on baseline
CT have a recommended follow-up time of 12-months,
patients with Lung-RADS 3 have a recommended
follow-up time of 6-months, and patients with Lung-
RADS 4 may have a 3-month recommended follow-up
time. Time from baseline CT to follow-up scan was re-
corded as a time interval measured in months. Adher-
ence to lung cancer screening was calculated using three
outcome measures: 1). Overall adherence was measured
dichotomously as “Did the patient come back for a sec-
ond LDCT at all?”, 2). Mean time (in months) to follow-
up CT chest was measured among patients who were
adherent overall, and 3). Timely adherence was mea-
sured, as “Did the patient come back for follow-up
within ± 30 days of the recommended time frame?”
Among patients who were eligible for continued lung
cancer screening or nodule surveillance (defined as no
diagnosis of screen-detected lung cancer, no change in
screening eligibility, and no death), long-term adherence
Fig. 1 CONSORT Diagram Displaying Sample Population
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status at the end of the study period were also measured.
We defined “lost to follow-up” status as patients who are
eligible for continued screening or nodule surveillance
and had not returned for repeat CT within a timeframe
30 days beyond the recommended follow-up interval (i.e.
13 months for Lung-RADS 1 and 2, 7 months for Lung-
RADS 3, etc.).
Main independent variable
Race was dichotomized (1 = white; 2 = black).
Covariates
Demographic, behavioral, and medical data were col-
lected from patients’ existing EMR. We included the fol-
lowing covariates: 1) age as of entry into database, 2) sex
defined as male or female, 3) body mass index (BMI), 4)
chronic obstructive pulmonary disease (COPD) which
was a dichotomous variable coded as yes and no/un-
known, 5) family history of lung cancer, a nominal vari-
able (yes and no/unknown) included lung cancer history
in a patient’s immediate or extended family, 6) smoking
status which consisted of current smoker, former
smoker, or current status unknown, and 7) pack-years a
numeric variable calculated by multiplying the number
of packs smoked per day by the number of years
smoked. These covariates were included in the study as
they are known risk factors for lung cancer [28–31] and,
therefore, may influence screening behaviors.
Geocoding
Home addresses of all referred patients who resided in
Philadelphia (n = 530) were geocoded by planning dis-
trict. Socioeconomic data [32] at the Philadelphia Plan-
ning District-level were joined with patient-level data, in
order to identify neighborhood-level predictors of LDCT
screening. Multilevel and multivariable logistic regres-
sion models were used to identify the individual and
neighborhood-level correlates of LDCT screening among
those referred to the LCSP. These neighborhood-level
variables were highly inter-correlated, ranging from 0.33
to 0.86. We created an index to capture neighborhood
disadvantage. This latent variable was created through
factor analysis and Varimax, an orthogonal rotation
method. The deprivation variable reflects high leadings
(> 0.70) on variables including percentage of adults 18–
64 years old without health insurance, percentage of
population living in a household with an income below
100% of the Federal Poverty Line, percentage of popula-
tion greater than or equal to 16 years old who are un-
employed, but seeking employment, and percentage of
adults over 25 years who completed at least some college
(n = 4, alpha = 0.75). The measure percent black (2.5 to
93.4%) was not included in the index of neighborhood
disadvantage due to low factor loading.
Statistical analysis
We used descriptive and analytic statistical methods
to present the findings of this study. Frequency and
cross-tabulation were used to summarize descriptive
data statistics in tables. First, we examined the out-
comes (e.g., underwent screening, follow-up time) by
race, only including whites and blacks (of any ethni-
city) using Chi-square statistics and t-test. Second, we
analyzed both race and known confounders to gain a
better understanding of the full scope of racial dispar-
ities of undergoing LDCT. Multivariate logistic regres-
sion was used to determine if race was a significant
predictor for undergoing LDCT after referral while
controlling for potential confounders. Finally, we con-
ducted a multilevel analysis to examine the effect of
both patient-level and neighborhood-level correlates
on undergoing LDCT among Philadelphia residents.
Stata version 14 was used [33].
Results
Sample demographics
Over the study period, 728 patients were referred to the
Jefferson LCSP. For this study, which examines screen-
ing outcomes among black and white patients only, 53
non-black and non-white patients were excluded from
analyses (Fig. 1). Following this, 675 participants
remained, for whom the mean age was 64.3 ± 5.9 years.
Over half of the patients referred to the LCSP were fe-
male (n = 366, 54.2%). Blacks made up 46.7% (n = 315) of
the cohort and whites made up 53.3% (n = 360)
(Table 1).
Race and LDCT status among patients referred to the
LCSP
Of the 675 black and white patients referred to the pro-
gram, 477 underwent lung cancer screening. Among the
black patients referred to lung cancer screening, 36.2%
were not screened compared to 23.3% of whites (x2 =
13.40, p < 0.001). A simple logistic regression showed
that blacks had significantly lower odds of receiving
screening compared to whites after referral for lung can-
cer screening (OR = 0.537, 95% CI, 0.384, 0.750)
(Table 2). In a multivariate logistic regression, blacks
had significantly lower odds of receiving screening than
whites after referral for lung cancer screening after con-
trolling for age, sex, BMI, COPD, family history of lung
cancer, and smoking status (aOR = 0.483, 95% CI, 0.331,
0.707).
In the subset of patients who resided in 16 of Philadel-
phia’s 18 planning districts (n = 530), multilevel model-
ing showed that a composite measure of neighborhood
disadvantage was marginally associated with receiving
screening: Those who live in planning districts with a
high level of neighborhood disadvantage had a trend
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toward lower odds of undergoing LDCT (OR = 0.53, 95%
CI 0.26–1.09, p = 0.084, Table 3, Model 2). In a model of
both individual- and neighborhood-level race, patient
race was the strongest predictor of undergoing LDCT
(aOR = 0.50, 95% CI: 0.3–0.82) (Model 3). We noted an
interaction between the variables patient race and
%black population at the neighborhood level. In a model
omitting the variable patient race (Model 4), the per-
centage of blacks residing in planning districts was inde-
pendently associated with receipt of lung cancer
screening, with subjects living in high %black neighbor-
hoods demonstrating lower odds of completing
Table 1 Demographic Characteristics of Patients Referred to the LCSP
All Referred Patients
(n = 675)
Black Patients
(n = 315)
White Patients
(n = 360)
Mean Age ± SD 64.3 ± 5.9 63.8 ± 5.9 64.6 ± 6.0
Sex
• Female 366 (54.2%) 193 (61.3%) 173 (48.1%)
• Male 309 (45.8%) 122 (38.7%) 187 (51.9%)
Mean BMI ± SD 28.5 ± 6.2 29.1 ± 6.7 27.9 ± 5.6
COPD
• Yes 214 (31.7%) 101 (32.1%) 113 (31.4%)
• No/Unknown 461 (68.3%) 214 (67.9%) 247 (68.6%)
Family History of Lung Cancer
• Yes 113 (16.7%) 49 (15.6%) 64 (17.8%)
• No/Unknown 562 (83.3%) 266 (84.4%) 296 (82.2%)
Smoking Status
• Current Smoker 375 (55.6%) 202 (64.1%) 173 (48.1%)
• Former Smoker 275 (40.7%) 108 (34.3%) 167 (46.4%)
• Unknown 25 (2.8%) 5 (1.6%) 20 (5.6%)
Mean Pack-Years ± SD 46.3 ± 25.8 40.6 ± 20.6 52.5 ± 29.3
Table 2 Results of Logistic Regression Analysis of Having LDCT Among Patients Who Were Referred to the LCSP
Patients Who Underwent Screening Patients Who Did Not Undergo Screening
n (%) n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)*
Race
• Black 201 (63.8%) 114 (36.2%) 0.537 (0.384–0.750) 0.483 (0.331–0.707)
• White 276 (76.7%) 84 (23.3%) 1.00 1.00
Age 1.001 (0.970–1.032)
Sex
Male 1.00
Female 0.986 (0.689–1.409)
BMI 1.001 (0.972–1.029)
COPD
No 1.00
Yes 1.246 (0.848–1.832)
Family History of Lung Cancer
No 1.00
Yes 1.107 (0.687–1.783)
Smoking Status
Current 1.00
Former 0.821 (0.572–1.170)
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screening (OR = 0.55, 95% CI 0.37–0.83). Moreover,
black patients living in high %black neighborhoods had
the lowest odds of undergoing LDCT (OR = 0.41, 95%
CI 0.26–0.65) (Model 5), compared with white patients
and black patients living in low %black neighborhoods.
Baseline demographics of screened patients
Among patients enrolled in the LCSP and who com-
pleted screening (n = 477), 42.1% were black (n = 201)
and 57.9% were white (n = 276) (Table 4). There was no
significant difference in mean age between blacks and
whites, at 64.2 vs. 64.3 years, respectively (p = 0.94).
There was a significant difference in race and sex among
screening participants, with a higher proportion of men
among whites (n = 149, or 54.0%) compared with the
proportion of men among blacks (n = 75, or 37.3%). In
contrast, women made up a higher proportion of blacks
(n = 126, or 62.7%) compared to that of whites (n = 127,
or 46.0%) who underwent screening (p < 0.001) (Table
4). White patients had a significantly higher mean pack-
year smoking history compared to blacks (53.1 vs. 43.4
pack-years, p < 0.001). Despite lower smoking intensity,
a greater proportion of blacks were current smokers
compared to whites (64.0% vs. 54.1%, p = 0.033). The
vast majority of patients in the LCSP had active health
insurance (95.6%) (Supplemental Table 1). The most
common insurance type among all screened patients was
Medicare Only (37.9%), followed by Private Only (26.0%)
and Medicaid / Dual Eligible (18.7%). The distribution of
Lung-RADS categories differed between black and white
patients, with a trend toward significance (p = 0.076)
(Supplemental Table 2).
Among patients with a negative result on baseline LDCT,
black patients had a longer interval to subsequent annual
screening compared with white patients
Among patients with a Lung-RADS category 1 result on
baseline screening LDCT, 46.7% (n = 85) were black and
53.3% (n = 97) were white (Table 5). Annual adherence
overall to lung cancer screening was low between both
races; just 17.6% (n = 15) of blacks and 19.6% (n = 19) of
whites returned at all to the program for their annual
scan after baseline. Among patients who did return,
black patients had a slightly longer but non-statistically
significant time interval from baseline LDCT to subse-
quent annual screening LDCT (13.33 months, SD = 1.02)
compared to whites (12.89 months, SD = 2.24). Timely
adherence rates were lower among blacks (n = 5, 33.3%)
compared to whites (n = 11, 57.9%), but this difference
was not statistically significant.
A greater racial difference was seen among patients
with Lung-RADS category 2 on baseline LDCT (n =
225), with almost twice as many whites (64%) as blacks
(36%) in this group. As seen with Lung-RADS 1, the
proportion of men undergoing screening was signifi-
cantly higher among whites than blacks, with the reverse
Table 3 Results of Multilevel Analysis of Having LDCT Among Those Living in Philadelphia Planning Districts (n = 530)
Model 1
Odds Ratio (95%
Confidence Interval)
Model 2a
Odds Ratio (95%
Confidence Interval)
Model 3a
Odds Ratio (95%
Confidence Interval)
Model 4a
Odds Ratio (95%
Confidence Interval)
Model 5a
Odds Ratio (95%
Confidence Interval)
Individual Level
Race
• Black 0.44 (0.30–0.65)** 0.50 (0.32–0.77)** 0.50 (0.30–0.82)** N/A
• White 1.00 1.00 1.00
Neighborhood Level
Neighborhood Disadvantageb 0.53 (0.26–1.09)+
%blacksc
low (2.5–24.2%) 1.00 1.00
high (39.5–93.4%) 0.82 (0.50–1.33) 0.55 (0.37–0.83)**
Race x %blacks
whites/low %blacks 1.00
white/high %blacks 0.99 (0.37–2.63)
blacks/low%blacks 0.54 (0.29–0.99)*
blacks/high%blacks 0.41 (0.26–0.65)**
Log Likelihood − 314.75 − 283.58 − 294.19 − 293.84 −290.03
Note. +p < .10; *p < .05; **p < .01
a Adjusted for known lung cancer risk factors: age, gender, BMI, COPD, family history of lung cancer, and smoking status
b Composite measure of neighborhood disadvantage (%of adults without health insurance, %of population living in a household with an income below 100% of
the Federal Poverty Line, %of unemployment, and %of less than some college)
c Median split of %blacks (low vs. high)
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Table 5 Adherence to Follow-Up Among Patients with a Negative Baseline Screen
Lung-RADS 1
Black Patients
n = 85
White Patients
n = 97
p-value
Mean Age ± SD 63.8 ± 5.7 64.7 ± 6.0 0.287
Sex
• Female 54 (63.5%) 43 (44.3%) 0.010
• Male 31 (36.5%) 54 (55.7%)
Overall adherencea, n (%) 15 (17.6%) 19 (19.6%) 0.738
Time to follow-up CTb, mean mos ± SD 13.3 ± 1.0 12.9 ± 2.2 0.493
Timely adherencec, n (%) 5 (33.3%) 11 (57.9%) 0.154
Lung-RADS 2
Black Patients
n = 81
White Patients
n = 144
p-value
Mean Age ± SD 63.7 ± 6.2 63.8 ± 6.0 0.922
Sex
• Female 56 (69.1%) 73 (51.0%) 0.008
• Male 25 (30.9%) 70 (49.0%)
Overall adherencea, n (%) 17 (21.0%) 30 (20.8%) 0.978
Time to follow-up CTb, mean mos ± SD 15.3 ± 4.8 12.7 ± 2.3 0.015
Timely adherencec, n (%) 4 (23.5%) 11 (57.9%) 0.002
a Overall adherence was defined as any follow-up CT chest following the baseline LDCT
b Time to follow-up was measured among screened patients who were adherent with any follow-up CT
c On-time adherence was defined as a follow-up CT within 30 days of the recommended time-frame for follow-up (13 months for Lung-RADS 1 or 2)
Table 4 Demographic Characteristics of Patients Screened by the Lung Cancer Screening Program
All Screened Patients
(n = 477)
Black Patients
(n = 201)
White Patients
(n = 276)
p-value
Mean Age ± SD 64.3 ± 5.9 64.1 ± 6.0 64.3 ± 5.9 0.943
Sex < 0.001
• Female 253 (53.0%) 126 (62.7%) 127 (46.0%)
• Male 224 (47.0%) 75 (37.3%) 149 (54.0%)
Mean BMI ± SD 28.5 ± 6.1 29.4 ± 6.6 27.9 ± 5.7 0.015
COPD 0.144
• Yes 158 (33.1%) 74 (36.8%) 84 (30.4%)
• No 319 (66.9%) 127 (63.2%) 192 (69.6%)
Family History of Lung Cancer 0.530
• Yes 82 (17.2%) 32 (15.9%) 50 (18.1%)
• No 395 (82.8%) 169 (84.1%) 226 (81.9%)
Smoking Status 0.033
• Current Smoker 273 (57.2%) 128 (63.7%) 145 (52.5%)
• Former Smoker 196 (41.1%) 73 (36.3%) 123 (44.6%)
• Unknown 8 (1.6%) 0 (0.0%) 8 (2.8%)
Mean Pack-Years ± SD 48.5 ± 23.9 43.4 ± 18.1) 53.1 ± 27.3 < 0.001
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true among women (p = 0.008) (Table 5). Overall adher-
ence to annual LDCT was slightly higher in Lung-RADS
2 than in Lung-RADS 1, but remained low overall; 17
(21.0%) blacks and 30 (20.8%) of whites returned to the
LCSP for an annual LDCT. Blacks had a significantly
longer mean time interval from baseline LDCT to subse-
quent annual screening LDCT (15.31 ± 4.81 months)
compared with whites (12.72 ± 2.27 months, p = 0.015).
Among patients with a positive result on baseline LDCT,
Black patients had a trend toward less timely adherence
and greater loss to follow-up
On baseline screening LDCT, 43 patients had a Lung-
RADS category 3 result (Table 6). There were no signifi-
cant differences in age or sex by race among those with
Lung-RADS 3, and 90.5% (n = 19) of black patients and
90.9% (n = 20) of white patients were adherent overall
with the short-interval follow-up CT scan. Again, blacks
had a longer mean follow-up interval, at 8.5 months
(SD = 4.5) vs. 6.6 months (SD = 3.0) for whites. A lower
proportion of blacks (n = 12, or 63.2%) than whites (n =
16, or 80.0%) had timely adherence to follow-up scan –
which we defined as within the ACR-recommended 6
months follow-up time with an additional 30-day win-
dow. Among patients eligible for return to annual screen-
ing or continued nodule surveillance, there were no racial
differences in the proportion of patients who were adher-
ent with subsequent scans or were lost to follow-up.
The smallest Lung-RADS group was Lung-RADS 4,
consisting of 14 black patients and 13 whites (Table 6).
Table 6 Adherence to Follow-Up Among Patients with a Positive Baseline Screen
Lung-RADS 3
Black Patients
n = 21
White Patients
n = 22
Mean Age ± SD 65.1 ± 5.7 65.1 ± 5.0
Sex
• Female 11 (52.4%) 8 (36.4%)
• Male 10 (47.6%) 14 (63.6%)
Overall adherencea, n (%) 19 (90.5%) 20 (90.9%)
Time to follow-up CTb, mean mos ± SD 8.5 ± 4.5 6.6 ± 3.0
Timely adherencec, n (%) 12 (63.2%) 16 (80.0%)
Screen-detected cancer 2 (9.1%) 0 (0%)
Patients eligible for screening or nodule surveillance 18d 21e
• Return to annual screening or nodule surveillance 11 (61.1%) 12 (57.1%)
• Lost to follow-upf 7 (38.9%) 9 (42.9%)
Lung-RADS 4
Black Patients
n = 14
White Patients
n = 13
Mean Age ± SD 688 ± 5.8 65.2 ± 4.3
Sex
• Female 5 (35.7%) 3 (23.1%)
• Male 9 (64.3%) 10 (76.9%)
Overall adherencea, n (%) 14 (100%) 13 (100%)
Time to follow-up CTb, mean mos ± SD 3.1 ± 2.9 2.1 ± 1.5
Timely adherencec, n (%) 10 (71.4%) 10 (76.9%)
Screen-detected cancer 5 (35.7%) 3 (30.8%)
Patients eligible for screening or nodule surveillance 9 9
• Return to annual screening or nodule surveillance 3 (33.3%) 6 (66.7%)
• Lost to follow-upf 6 (66.7%) 3 (33.3%)
a Overall adherence was defined as any follow-up CT chest following the baseline LDCT
b Time to follow-up was measured among screened patients who were adherent with any follow-up CT
c On-time adherence was defined as a follow-up CT within 30 days of the recommended time-frame for follow-up (4 months for Lung-RADS 3 or 4)
dOne black, Lung-RADS 3 patient became ineligible during the follow-up period due to smoking cessation > 15 years prior
eOne white, Lung-RADS 3 patient died during the follow-up period
f Lost to follow-up was defined by current status
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There were no significant differences in age or sex be-
tween blacks and whites who were assigned Lung-RADS
4, and 100% of Lung-RADS 4 patients returned for a
follow-up scan. Review of the electronic health record
revealed that all patients were recommended for either
immediate PET-CT scan or short-interval follow-up CT
at 3 months. Blacks again demonstrated a longer follow-
up time than whites (3.1 months vs. 2.1 months, p =
0.289). Blacks also had a lower percentage of on-time
adherence (returning ±30 days of recommended three-
month follow-up) compared to whites, with 71.4, and
76.9% timely adherence rates, respectively. More blacks
with Lung-RADS 4 on baseline (n = 5, 35.7%) were diag-
nosed with lung cancer compared to whites (n = 4,
30.8%). Only 3, or 33.3% of black patients who were eli-
gible to return for screening returned, compared to 6, or
66.7% whites. A greater proportion of blacks (n = 6, or
66.7%) than whites (n = 3, or 33.3%) were lost to follow-
up after completing their initial recommended manage-
ment strategy.
Discussion
We have shown that clinically important disparities exist
between black and white patients undergoing lung can-
cer screening with LDCT within our LCSP in Philadel-
phia. Black patients who were referred to our program
had significantly lower odds of receiving LDCT com-
pared to white patients after controlling for covariates.
Moreover, black patients who underwent a screening
LDCT demonstrated longer follow-up time intervals
compared with white patients across all Lung-RADS cat-
egories. Finally, black patients with Lung-RADS 4 had
lower rates of returning to annual screening and higher
rates of loss to follow-up compared with white patients.
To our knowledge, this is the only study as yet to exam-
ine lung cancer screening referrals and screening adher-
ence in the context of race.
However, there are some limitations to our study. Pri-
marily, this analysis looked only at black and white pa-
tients; further research should include other racial and
ethnic minorities as well as other vulnerable populations
at risk for lung cancer. Further, the LCSP requires pa-
tients to be referred by a healthcare provider, potentially
introducing a referral bias. While the study period cov-
ered a 27-month timeframe from May 2015 to July 2017,
our sample sizes, once stratified by Lung-RADS cat-
egory, were small. This hampered the types of statistical
analyses we were able to conduct. In addition, the small
sample size may have impacted our ability to identify
significant differences in time to follow-up, timely adher-
ence, cancer diagnosis, return to annual screening, or
lost to follow-up rates.
Not surprisingly, overall adherence to subsequent an-
nual screening was low for patients assigned Lung-
RADS 1 or 2 on baseline LDCT, regardless of race.
Compared to the NLST, Jefferson’s LCSP adherence rate
was much lower (95% vs. 19.9%, respectively) [3]. In a
highly structured clinical trial setting, NLST patients
were 4.77 times as likely to adhere to annual LDCT.
Among “real-world” lung cancer screening programs,
however, annual adherence rates between 0 and 60%
have been described. Among other types of cancer
screening, colorectal cancer screening adherence rates
around 65% are commonly reported, for example [34–
36]. Additional research is needed to identify how best
to maximize compliance with lung cancer screening and
improve adherence rates nationwide.
In contrast to patients with Lung-RADS 1 or 2 on
LDCT, patients with a positive result on baseline LDCT
in our LSCP had follow-up adherence rates between 90
and 100%. Among this subgroup, the rate of timely ad-
herence and the mean time to follow-up imaging may be
more clinically significant measures of characterizing
follow-up patterns among blacks and whites. Despite
high overall adherence among Lung-RADS 3 and 4 pa-
tients, timely adherence among all patients was not as
frequent, and on-time follow-up rates were lower among
blacks compared with whites.
Although we found that mean time to follow-up
scan across all Lung-RADS categories was longer
among black patients compared with white patients,
the absolute differences appear small. For example,
among patients with Lung-RADS 2 – those who
have a small nodule with a very low likelihood of
becoming a clinically active lung cancer and are rec-
ommended to continue annual screening with LDCT
in 12 months – a follow-up time of 15.3 months
among blacks vs. 12.7 months among whites may not
have major clinical significance. Despite this, the
trend of universally longer follow-up times across all
Lung-RADS categories underscores our finding that
black patients demonstrate a delay in returning for
care.
During the timeframe that the patients in this
study underwent screening, there was no consistent
method in place for sending reminders to patients
with negative screens to return at 12 months for
continued surveillance. Patients with Lung-RADS 3
or 4 did receive multiple phone calls and letters, no-
tifying them of required follow-up. Since January
2018, our LCSP has implemented a standardized ap-
proach to proactive scheduling of annual LDCTs and
notifying screened patients about overdue screens,
with the aim of improving annual adherence rates.
Adherence endpoints were less straightforward among
Lung-RADS 4 patients, for whom suspicious nodules
may require a short-interval CT chest or PET-CT, and/
or tissue sampling based on patients’ pre-test risk of
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lung cancer as determined by the LCSP steering com-
mittee and the Nodule Clinic. By using the next imaging
test ordered (CT or PET) and expected timeframe ex-
tracted from office notes, we were able to calculate
follow-up adherence. The time interval to the next im-
aging study is not representative of the extensive diag-
nostic workup for a patient with a suspicious nodule,
however. Although we focused on immediate follow-up
studies, others have reported that black patients have a
delay to diagnosis when undergoing evaluation for pos-
sible lung cancer [37, 38].
We did investigate longer-term outcomes, including
return to annual screening if follow-up imaging demon-
strated nodule stability or resolution. A minority of
Lung-RADS 3 and 4 nodules may continue to be
followed by a range of surveillance timeframes through
our Nodule Clinic, and we included these patients when
we determined follow-up rates [39]. While an endpoint
such as return to annual screening following a positive
baseline LDCT has not been reported in the lung cancer
screening literature to our knowledge, it is critical to in-
clude this subset of patients when calculating adherence
rates [40].
We were unable to identify a specific reason for the
lower odds of lung cancer screening among blacks re-
ferred to our program, or for the longer follow-up
times among blacks undergoing screening. In general,
barriers to lung cancer screening can include patient-,
provider-, and systems-related factors. Specifically, ac-
cess to care, socioeconomic status, and attitudes
about healthcare systems play a significant role [7, 41,
42]. Insurance status may be a barrier for patients
undergoing LDCT or adhering to the recommended
follow-up, especially for those who are underinsured
or uninsured [43]. The Affordable Care Act mandated
that Medicare and private payers cover services that
receive at least a “B” grade from the USPSTF [4, 5].
Furthermore, short-term follow-up visits may require
a copay depending on the specific insurance plan.
This study would be improved by analysis of
individual-level insurance status as a major variable in
lung cancer screening initiation and adherence, but
these data were not available for patients referred to
the program. In place of this, we carried out multi-
level modeling using neighborhood-level factors, in-
cluding the percentage of uninsured adults per
planning district. Consistent with the CHEST guide-
line and expert panel report, it is critical for LCSPs
to consider these issues to develop the most effective
program for the community [27].
It is important to note that while controlling for
known lung cancer risk factors that may influence
screening behavior, blacks still had lower odds of re-
ceiving lung cancer screening compared to whites.
Although we did not specifically account for covari-
ates related to socioeconomic status at the individual
level, we did take into account neighborhood-level
correlates. Neighborhood disadvantage, a composite of
four variables commonly associated with vulnerability,
marginally correlated with completing screening. Not-
ably we found the cross-level interaction between the
variables patient race and neighborhood %black,
which were each significantly associated with under-
going lung cancer screening in separate models.
These results suggest that for black patients – par-
ticularly those living in black-predominant neighbor-
hoods – interpersonal or community-related
behavioral and sociocultural domains may influence
individual health behaviors. Further research is
needed to explore the specific impact of these neigh-
borhood variables on lung cancer screening among
vulnerable populations. Specific barriers to lung can-
cer screening have been described among minority
patients, including patient-, provider-, and systems-
related barriers [43, 44]. Ongoing studies from our
group and others focuses on potential reasons blacks
are less likely to be screened for lung cancer after re-
ferral, including transportation and access issues, fi-
nancial burdens related to screening, and the role of
patient attitudes, perceptions, and beliefs about lung
cancer screening and cancer.
Recent studies among racially diverse, urban popu-
lations have described a variety of lung cancer screen-
ing outcomes. Pasquinelli and colleagues reported
that among the first 500 patients enrolled for screen-
ing through their inner-city, minority-based LCSP
(69.6% black), a higher frequency of positive LDCT
scans and a higher percentage of screen-detected lung
cancers was seen compared with the NLST [45]. In
contrast, Guichet and colleagues reported a nearly
identical rate of positive LDCT scans to that of the
NLST among a cohort of 275 minority (84% black)
and socioeconomically disadvantaged patients [46].
Likewise, our distribution of Lung-RADS categories
by race showed a non-significant difference between
black and white patients. (Supplemental Table 2) Fur-
thermore, black women had a higher frequency of
Lung-RADS 1, 2, or 3 results on baseline screen (121
of 187, or 65%) compared with black men, who had a
higher frequency of Lung-RADS 4 results (9 of 14, or
64%). These findings indicate the presence of race-
and sex-dependent features in lung cancer risk and
screening outcomes, which are being studied by our
group and others.
We also found that screen-detected lung cancers were
more frequent among black patients (7 of 201 patients
screened, or a screening yield of 3.5%) compared with
white patients (3 of 276 patients screened, or 1.1%). The
Lake et al. BMC Cancer          (2020) 20:561 Page 10 of 12
screen-detected cancer incidence among blacks in our
cohort is markedly higher than that of participants in
the NLST, for example [47]. In our cohort, black pa-
tients had a higher frequency of current smoking status
and COPD compared with white patients undergoing
lung cancer screening (Table 1). These differences high-
light the importance of identifying additional lung can-
cer risk factors that may disproportionately impact
blacks or other vulnerable populations. Multiple investi-
gators have suggested, for example, that black patients
would benefit from race-specific adjustment of screening
eligibility criteria [22, 48, 49]. Future research is needed
to confirm the preliminary trends identified in this
study.
Conclusions
We found that blacks who were referred to lung cancer
screening had lower odds of receiving LDCT compared
to whites. Our findings also suggest that black patients
at high-risk for lung cancer experience disparate care in-
cluding missed exams, poor adherence, and delayed
follow-up when they are referred for lung cancer screen-
ing. This is an essential difference that must be explored
further if we are to realize the imperative of reducing
lung cancer mortality in blacks across the United States.
Ongoing efforts to improve screening among vulnerable
populations should focus on identifying barriers that
contribute to these disparities.
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